The impact of COVID-19 on health status of home-dwelling elderly patients with dementia in East Lombardy, Italy: results from COVIDEM network

Salvatore Caratozzolo1 · Alberto Zucchelli2 · Marinella Turla3 · Maria Sofia Cotelli3 · Sara Fassendini4 · Mara Zanni4 · Angelo Bianchetti5,14 · Matteo Peli Psy5,14 · Renzo Rozzini6,14 · Stefano Boffelli6,14 · Melania Cappuccio7 · Federica Gottardi Psy7 · Chiara Vecchi Psy8 · Daniele Bellandi9 · Claudia Caminati9 · Simona Gentile10 · Elena Lucchi Psy10 · Ignazio Di Fazio11 · Marina Zanetti Psy11 · Giuliana Vezzadini12 · Chiara Forlani Psy12 · Maura Cosseddu Psy1 · Rosanna Turroni Psy1 · Silvia Pelizzari Psy1 · Andrea Scalvini1 · Marco Di Cesare1 · Marta Grigolo Psy5 · Lina Falanga6 · Nives Medici7 · Nives Palamini7 · Elisa Zanacchi Psy7 · Eleonora Grossi Psy10 · Giuseppe Bellelli13 · Alessandra Marengoni2 · Marco Trabucchi14 · Alessandro Padovani1 · On behalf of COVIDEM Network

Abstract

Background COVID-19 outbreak has led to severe health burden in the elderly. Age, morbidity and dementia have been associated with adverse outcome.

Aims To evaluate the impact of COVID-19 on health status in home-dwelling patients.

Methods 848 home-dwelling outpatients with dementia contacted from April 27 to 30 and evaluated by a semi-structured interview to evaluate possible health complication due to COVID-19 from February 21 to April 30. Age, sex, education, clinical characteristics (including diagnosis of dementia) and flu vaccination history were obtained from previous medical records. Items regarding change in health status and outcome since the onset of the outbreak were collected. COVID-19 was diagnosed in patients who developed symptoms according to WHO criteria or tested positive at nasal/throat swab if hospitalized. Unplanned hospitalization, institutionalization and mortality were recorded.

Results Patients were 79.7 years old (SD 7.1) and 63.1% were females. Ninety-five (11.2%) patients developed COVID-19-like symptoms. Non COVID-19 and COVID-19 patients differed for frequency of diabetes (18.5% vs. 37.9%, p < 0.001), COPD (7.3% vs. 18.9%, p < 0.001), and previous flu vaccination (56.7% vs. 37.9%, p < 0.001). Diabetes and COPD were positively associated with COVID-19, whereas higher dementia severity and flu vaccination showed an inverse association. Among COVID-19 patients, 42 (44.2%) were hospitalized while 32 (33.7%) died. Non COVID-19 patients’ hospitalization and mortality rate were 1.9% and 1.2%, respectively. COVID-19 and COPD were significantly associated with the rate of mortality.

Discussion/conclusions A high proportion of adverse outcome related to COVID-19 was observed in home-dwelling elderly patients with dementia. Active monitoring though telehealth programs would be useful particularly for those at highest risk of developing COVID-19 and its adverse outcomes.

Keywords COVID-19 · Dementia · Home dwelling · Health status

Introduction

The outbreak of coronavirus disease 2019 (COVID-19) hit Italy by the end of February and rapidly spread from Lombardy to the rest of the country, with a number of fatalities beyond 31,000. The COVID-19 outbreak is currently leading to severe health burden, in particular in Lombardy, the
region with the highest number of infected people, highest number of hospitalization and deaths [1].

Although all regions reporting having patients with COVID-19, the highest number of identified cases was in the provinces of eastern Lombardy, including Bergamo, Brescia and Cremona. Case-fatality rate steeply increases with age worldwide, where half of the deaths occurred in people aged 80 years or above [2, 3]. Dementia is highly prevalent among very old people (i.e., octogenarians) and is therefore expected to be particularly common among people who had the highest case-fatality rate related to COVID-19. Nonetheless, only a few studies have focused on the impact of COVID-19 on dementia. Importantly, demented subjects might be at higher risk of adverse events because they are generally old, are affected by multiple morbidities, have difficulty recognizing signs of infection, have limited access to information about COVID-19, and have difficulties in remembering safeguard procedures, thus ignoring the warnings and being exposed to higher chance of infection [4, 5]. As far as Italy is concerned, due to the outbreak, most outpatients’ clinics, including the Center of Dementia and Cognitive Decline (CDCD), were closed after the suspension of deferred outpatient visits and the extension of treatment plans according to the regional decrees. Patients and their caregivers were neither included in national health care programs or in regional health initiatives for active monitoring by telemedicine. Nevertheless, to accomplish patients’ needs and clinical issues, in several CDCDs of the provinces of the Eastern Lombardy initiatives for remote listening, teleconsultation and telemedicine have been carried out. These initiatives have allowed maintaining in many cases a contact with the majority of patients followed up by the CDCD. Accordingly, most of these centres agreed to record clinical data routinely obtained through an interview in outpatients with cognitive decline or dementia.

The aim of this study was to evaluate the impact of the COVID-19 outbreak on the health status of a large sample of home-dwelling elderly with dementing illness, by investigating the rate of COVID-19 symptoms, rate of hospitalization and mortality. Clinical characteristics of patients from medical records and COVID-19-related prognostic factors were evaluated.

**Participants and procedure**

This is an observational study carried out in home-dwelling patients with dementia who were periodically visited at the CDCD. These are specialist centres in connection with general practitioners (GPs), which have been established across the country and are dedicated to the diagnosis and management of patients for all forms of dementia across the entire complex staging spectrum. The sample included outpatients with a complete medical record before the beginning of the COVID-19 outbreak in Italy (February 21). Eleven CDCDs from Eastern Lombardy were selected according to their involvement in teleconsulting activities and accepted to participate and to perform a structured interview during the last week of April (27–30 April 2020). The interview (Supplementary Material) was carried out by a physician and a psychologist and was part of the routine evaluation to assist and care patients during the suspension of outpatient clinic. In case of moderate to severe cognitive impairment or severe COVID-19 disease, the interview was administered both to patients and proxy/caregiver. All data were anonymously aggregated.

The Ethical Committee of the Brescia County approved the study.

**Data collection**

Information on age, sex, education, clinical characteristics including dementia diagnosis, dementia severity by Clinical Dementia Rating scale (CDR) [6], Mini Mental State Examination (MMSE) [7], and Basic Activity of Daily Life (BADL) [8], walking, total number of chronic diseases and type of diseases among a pre-defined list (hypertension, COPD, renal disease, heart disease, cancer, gastrointestinal diseases, hepatic disease, diabetes, thyroid disorders, arthritis), number of drugs, and flu vaccination were obtained from previous medical records based on the last recorded visit at CDCD. The semi-structured interview included items regarding change in health status, unplanned hospitalization and mortality in the previous 2 months, thus since the onset of the Italian outbreak (February 21). About the health status, symptoms and signs of possible COVID-19 infection (fever, cough, headache, dyspnoea, weakness, gastrointestinal problems) were collected. Patients were classified as affected by COVID-19, either if they had a positive swab test or a suspected infection according to WHO definition [9]. In particular, patients were considered to be affected by COVID-19 (a) if patients had a referred acute respiratory illness or COVID-like infection (fever and at least one sign/symptom of respiratory disease, such as cough, shortness of breath, dyspnoea, sore throat), AND with no other aetiology that fully explains the clinical presentation AND either a history of travel to or residence in a country/area or territory reporting local transmission of COVID-19 disease during the 14 days prior to symptom onset; (b) if patients had a severe acute respiratory infection (fever and at least one symptom or sign of respiratory diseases such as coughing and difficulty breathing) that required hospitalization for severe acute respiratory infection (SARI), with no other aetiology that fully explains the clinical presentation.
Statistical analysis

The study population’s characteristics were described using mean and standard deviation or absolute number and proportion. Differences between groups were explored using t tests or \( \chi^2 \) test, as appropriate. Odds ratios (ORs) and their 95% confidence intervals (95% CI) were obtained using multivariable logistic regression models testing factors associated with COVID-19 and mortality. Variables significant at univariate analysis or considered clinically important according to the outcome of interest were included in the multivariate models. An alpha level of 0.05 was considered to be statistically significant for the analyses. Data analyses were carried out using SPSS software (version 22.0) and R (version 4.0.0; R Core Team, Wien-Austria).

Results

In total, 900 patients were contacted from ten CDCCD. Among them, 26 patients were missing, 10 patients refused to participate, and 16 patients were unable to give reliable information. The final sample of the study included 848 patients. As shown in Table 1, patients were on average 79.7 years old (SD 7.1), 63.1% were females, and 59.7% had primary education. According to historical data referred to the last valid visit (mean time from last visit and interview was 16.5 SD 8.3 weeks), mean CDR was 1.5 (SD 0.9) and mean MMSE was 18.7 (SD 6.8). The mean number of chronic diseases was five (SD 2.8) and the most frequent were hypertension (71.3%), cardiovascular disease (35.1%), type 2 diabetes mellitus (20.6%), cancer (16.3%) and chronic obstructive pulmonary disease (COPD) (8.5%). The mean number of drugs was 5.5 (SD 2.8). Flu vaccination was reported in 463 patients (54.6%). According to medical records, 144 (17%) were patients affected by mild cognitive impairment (MCI), 331 (39%) by Alzheimer disease, 202 (23.8%) by mixed dementia, and 171 (20.2%) by other dementing illnesses, including fronto-temporal dementia, Lewy-body dementia, and vascular dementia.

Ninety-five (11.2%) patients developed COVID-19 symptoms. Nasopharyngeal swab was performed in the whole sample of 57 hospitalized subjects. Forty-seven subjects were classified as COVID-19 positive only on suggestive symptoms with epidemiologic criteria; 16 patients with SARI symptoms were hospitalized; of those, 12 were positive at nasopharyngeal swab, while 4 patients were negative; 7 patients remained at home and were not investigated.

NonCOVID-19 and COVID-19 patients differed in CDR (1.6 SD 0.9 vs. 1.3 SD 0.9; \( p = 0.017 \)), MMSE (18.6 SD 6.9 vs. 20.5 SD 5.8 \( p = 0.01 \)), frequency of diabetes (18.5% vs. 37.9%, \( p < 0.001 \)), COPD (7.3% vs. 18.9%, \( p < 0.001 \)), and previous flu vaccination (56.7% vs. 37.9%, \( p < 0.001 \)), while the two groups were comparable for age, gender, number of diseases, number of drugs, and BADL.

As shown in Table 2, diabetes (OR 3.1; CI 1.92–5.11) and COPD (OR 2.8; CI 1.51–5.16) were significantly associated with COVID-19 infection, whereas hypertension (OR 0.6; CI 0.35–0.94), moderate to severe dementia (OR 0.49, CI 0.27–0.91) and flu vaccination (OR 0.47; CI 0.29–0.74) were negatively associated with COVID-19 infection.

As reported in the flowchart of the study (Fig. 1), 42 (44.2%) COVID-19 patients were hospitalized whereas 6 COVID-19 patients were placed in a nursing home. None of non COVID-19 patients was institutionalized during the observation period. Thirty-two (33.7%) COVID-19 patients died (at home = 11; in hospital = 21) including 19 patients for SARI, 8 patients for myocardial infection and 5 patients

### Table 1: Demographic and Clinical Characteristic of the whole sample and grouped by COVID-19 infection/non infection

| Variable               | Overall       | non-COVID-19 | COVID-19   | \( p \) |
|------------------------|---------------|--------------|------------|--------|
| \( N \)=848            |               | \( N \)=753   | \( N \)=95  |        |
| Age (mean (SD))        | 79.7 (7.1)    | 79.8 (7.1)   | 79.2 (7.5) | NS     |
| Women (%)              | 535 (63.1)    | 476 (63.2)   | 59 (62.1)  | NS     |
| Diagnosis (%)          |               |              |            |        |
| MCI (%)                | 144 (17.0)    | 127 (16.9)   | 17 (17.9)  | NS     |
| Alzheimer disease (%)  | 331 (39.0)    | 303 (40.2)   | 28 (29.5)  | NS     |
| Mixed (%)              | 202 (23.8)    | 179 (23.8)   | 23 (24.2)  | NS     |
| Other (%)              | 171 (20.2)    | 91 (12.1)    | 16 (16.8)  | NS     |
| CDR (SD)               | 1.5 (0.9)     | 1.6 (0.9)    | 1.3 (0.9)  | 0.017  |
| CDR 0.5 (%)            | 230 (27.1)    | 197 (26.2)   | 33 (34.7)  |        |
| CDR 1 (%)              | 198 (23.3)    | 172 (22.8)   | 26 (27.4)  |        |
| CDR 2 (%)              | 255 (30.1)    | 232 (30.8)   | 23 (24.2)  |        |
| CDR 3 (%)              | 165 (19.5)    | 152 (20.2)   | 13 (13.7)  |        |
| MMSE (SD)              | 18.7 (6.8)    | 18.6 (6.9)   | 20.5 (5.8) | 0.010  |
| BADL Lost (SD)         | 5.0 (2.8)     | 5.1 (2.8)    | 4.7 (2.8)  | NS     |
| Number of Diseases (SD)| 5.5 (2.9)     | 5.5 (2.8)    | 5.3 (2.8)  | NS     |
| Hypertension (%)       | 605 (71.3)    | 544 (72.2)   | 61 (64.2)  | NS     |
| Diabetes Mellitus (%)  | 175 (20.6)    | 139 (18.5)   | 36 (37.9)  | <0.001 |
| COPD (%)               | 72 (8.5)      | 55 (7.3)     | 18 (18.9)  | <0.001 |
| Heart Diseases (%)     | 298 (35.1)    | 265 (35.2)   | 33 (34.7)  | NS     |
| Liver Disease (%)      | 73 (8.6)      | 65 (8.6)     | 9 (9.5)    | NS     |
| Kidney Disease (%)     | 79 (9.3)      | 65 (8.6)     | 14 (14.7)  | NS     |
| Flu Vaccination (%)    | 462 (54.5)    | 427 (56.7)   | 36 (37.9)  | 0.001  |
| Hospitalisation (%)    | 57 (6.7)      | 15 (2.0)     | 42 (44.2)  | <0.001 |
| Institutionalization (%)| 8 (0.9)       | 1 (0.1)      | 7 (7.4)    | <0.001 |
|死亡 (%)               | 41 (4.8)      | 9 (1.2)      | 32 (33.7)  | <0.001 |
As shown in Table 3, compared to survivors, patients who died showed milder dementia severity according to CDR and MMSE, but not age, gender, number of diseases and drug differences, whereas they differed in terms of frequency of hypertension, COPD and COVID symptoms.

In multivariate model testing factors associated with mortality, only COVID-19 symptoms (OR 94.5; 95% CI 31.0–287.9) and COPD (OR 3.7; 95% CI 1.21–11.43) were significantly associated.

**Discussion**

Findings from our study showed that COVID-19 affected over 10% of home-dwelling older patients with dementia who showed high risk of adverse outcomes, such as unplanned hospitalization and mortality. COVID-19 was more frequently reported in patients with diabetes and COPD, whereas hypertension, dementia severity and anti-flu vaccination were significantly associated with lower likelihood of COVID-19. Further, COVID-19 and COPD were strongly associated with mortality. To the best of our knowledge, this is the first study that investigated the impact

---

**Table 2** Odds ratios (OR) and 95% confidence intervals (95% CI) for having COVID-19

| Factor               | OR    | 95% CI     |
|----------------------|-------|------------|
| Age (years)          | 0.9   | 0.96–1.02  |
| Sex, male            | 1.1   | 0.69–1.75  |
| Hypertension         | 0.6   | 0.35–0.94  |
| Diabetes mellitus    | 3.1   | 1.92–5.11  |
| COPD                 | 2.8   | 1.51–5.16  |
| CDR                  |       |            |
| 0.5 (reference)      | 1     |            |
| 1                    | 0.8   | 0.46–1.53  |
| 2                    | 0.49  | 0.27–0.91  |
| 3                    | 0.49  | 0.24–1.01  |
| Flu vaccination       | 0.47  | 0.29–0.74  |

*COPD* chronic obstructive pulmonary disease, *CDR* clinical dementia rating scale

---

Fig. 1 Flowchart of the study population
of COVID-19 on the health status of home-dwelling patients with dementia.

We used data collected during this emergency period to identify home-dwelling patients with dementia who developed COVID-19 and to test the hypothesis that they were at high risk of suffering an adverse outcome [2]. Findings of this study are in line with previous reports [10–12] and add new insight by showing that COVID-19 exerted a relevant impact on health status of home-dwelling elderly patients with dementia determining a high rate of hospitalization and mortality.

In this study, the proportion of patients that developed COVID-19 was close to the rates estimated [13, 14] in Lombardy (about 13%). In fact, in our survey 11.2% of the sample reported COVID-19 symptoms during the outbreak. These data argue for the effectiveness of the lockdown in limiting COVID-19 spreading among home-dwelling elderly, though asymptomatic cases and atypical cases might have been not properly identified, thus cases might be underestimated [15, 16]. In fact, it has been shown that in older and frail individuals such as those with dementia, infections may present without fever, cough, chest discomfort or other signs of inflammation [17, 18].

Previous findings have underlined that several factors are associated with COVID-19 including older age, metabolic and cardiovascular disease, and COPD [19–24]. In this study, COVID-19 was more frequent in patients with diabetes and COPD, whereas neither age nor gender predicted COVID-19 symptoms and adverse events. These findings are likely due both to the old age of the sample and to multiple morbidity, whereas the apparent protective effect of hypertension on COVID-19 might be due to a possible role of antihypertensive medications [25, 26]. As the study design does not allow to draw any conclusion, further studies are needed to disentangle the complex relationship between hypertension and risk COVID-19. At variance of literature data [4, 5], patients with advanced dementing illnesses were at lower risk to suffer COVID-19 and had less adverse events. There are several speculative explanations for this finding. First, in more advanced patients, preventive measures such as isolation and social distance might have been more strictly applied or, likely, patients with advanced dementia are those who were already confined at home since the beginning of the outbreak given their poor functional status. Secondly, we cannot rule out that patients with severe dementia had typical or atypical symptoms not recognized by caregivers as possibly associated with COVID-19 and thus not reported during the interview.

An important finding of the study is that flu vaccination was significantly associated with a lower risk of developing COVID-19. Flu vaccination was reported in about 54% of this sample, which is very close to the national coverage (53.1%) in the elderly population reported by Italian “Istituto Superiore Sanità” (ISS) [27, 28]. No studies have looked so far at the effect of flu vaccination on COVID-19 incidence or severity among elderly individuals. These unexpected results support the hypothesis that resultant immunity against prior influenza infection might, at least in part, foster immunity against SARS-CoV-2, due to the similarity in their structures and that flu vaccination might generate sustained bystander immunity that overall enhances immunity against SARS-CoV-2, thus inducing milder forms of COVID-19 [29, 30]. However, although we found a reduced odds of COVID-19 due to flu vaccination, our study was not specifically designed to address this research question; in fact, we did not account for timing of administration or type of vaccine received, nor did we address other potential factors that may have biased our results [31]. In fact, patients or caregivers who get a vaccination usually pay more attention to their health status and may be more likely to have been compliant with preventive measures. Not surprisingly, the prognosis of COVID-19 among this sample of home-dwelling patients was poor, as almost half of the affected patients were hospitalized, while among those who did not develop COVID-19 hospitalization was less than 2%, in line with epidemiological data [32]. Moreover, overall mortality rate was 33.7% among COVID-19 patients and less than 2% among non-COVID-19 patients. These data confirm recent reports in the Italian population which have

### Table 3 Demographic and clinical characteristics of the sample according to fatality

| Variables            | Survivors | Not Survivors | p      |
|----------------------|-----------|---------------|--------|
| Age (mean (SD))      | 79.7 (7.1)| 80.4 (7.3)    | NS     |
| Women (%)            | 506 (62.7)| 29 (70.7)     | NS     |
| CDR (SD)             | 1.5 (0.9 )| 1.1 (0.7)     | 0.001  |
| CDR 0.5 (%)          | 214 (26.5)| 16 (39.0)     |        |
| CDR 1 (%)            | 185 (22.9)| 13 (31.7)     |        |
| CDR 2 (%)            | 245 (30.4)| 10 (24.4)     |        |
| CDR 3 (%)            | 163 (20.2)| 2 (4.9)       |        |
| MMSE (SD)            | 18.6 (6.8)| 21.4 (5.4)    | 0.011  |
| BADL lost (SD)       | 1.9 (2.1 )| 1.3 (1.8)     | 0.034  |
| Number of diseases (SD)| 5.1 (2.8) | 4.2 (2.3)     | NS     |
| Number of drugs (SD) | 5.5 (2.8 )| 4.8 (2.8)     | NS     |
| Hypertension (%)     | 595 (73.3)| 11 (26.9)     | <0.001 |
| Diabetes mellitus (%)| 165 (20.4)| 10 (24.4)     | NS     |
| COPD (%)             | 65.8 (8.1)| 8 (19.5)      | 0.019  |
| Heart diseases (%)   | 288 (35.7)| 9 (22.0)      | NS     |
| Liver disease (%)    | 72 (8.9)  | 2 (4.9)       | NS     |
| Kidney disease (%)   | 77 (9.5)  | 2 (4.9)       | NS     |
| Flu vaccination (%)  | 446 (55.3)| 17 (41.5)     | NS     |
| COVID infection (%)  | 63 (7.8)  | 32 (78)       | <0.001 |
| Hospitalisation (%)  | 37 (4.6)  | 20 (48.8)     | <0.001 |
shown that, in front of an overall fatality rate about 7%, the case-fatality rate of elderly patients is very high (i.e. 24% for decade 70–79 and 29% decade 80–89) [33, 34]. Further, our data strongly support the claim that patients with dementing illnesses are even at higher risk of adverse events due to COVID-19 [35] and that they require careful evaluation and specific interventions early in the progression of the COVID-19 symptoms. To accomplish such a preventive intervention, national programs aimed to maintain a constant monitoring of elderly with dementing illnesses and at higher risk of developing COVID-19 diseases should be developed through a standardized protocol by telemedicine.

First, only a minority of patients included in the study were specifically tested for SARS-CoV-2 infection, whereas the majority of those classified as having COVID-19 exhibited symptoms considered COVID-19-like according to the definition of the WHO. On the other hand, given the outbreak of COVID-19 in Lombardy during the time period considered and that a late-seasonal flu was unlikely, the likelihood of a correct diagnosis of COVID-19 in patients included is high. Secondly, we cannot exclude that during the severe and unexpected public health emergency, the most severely affected patients were not even admitted to hospitals and died at home undiagnosed.

Under this assumption, our results are underestimating the impact of COVID-19, but this hypothesis should be tested in future studies.

On the other hand, the major strengths of the study are the few missing data and the novelty of clinical characteristics analysed.

Conclusions

A high proportion of severe to critical cases of COVID-19 was observed in this large sample of home-dwelling elderly patients with dementia. Several patients’ conditions including diabetes, COPD, less severe dementing illness, and flu vaccination were associated with the risk of COVID-19. Close tele-monitoring and timely treatment of infection should be carried out as standardized care for home-dwelling elderly patients at high risk to prevent adverse events.

Funding  Open access funding provided by Università degli Studi di Brescia within the CRUI-CARE Agreement. No Funding to support this study was asked.

Data availability statement  The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Compliance with ethical standards

Conflict of interest  The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical approval  All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent  Informed consent was obtained from all participants.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fiorillo A, Gorwood P (2020) The consequences of the COVID-19 pandemic on mental health and implications for clinical practice. Eur Psychiatry 63:e32. https://doi.org/10.1192/j.eurpsy.2020.35
2. Onder G, Rezza G, Brusafarro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. https://doi.org/10.1001/jama.2020.4683
3. Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:934–943
4. Wang H, Li T, Barbarino P et al (2020) Dementia care during COVID-19. Lancet 395:1190–1191. https://doi.org/10.1016/S0140-6736(20)30755-8
5. Naumova EN, Parisi SM, Castronovo D et al (2009) Pneumonia and influenza hospitalizations in elderly people with dementia. J Am Geriatr Soc 57:2192–2199. https://doi.org/10.1111/j.1532-5415.2009.02565.x
6. Hughes CP, Berg L, Danziger WL et al (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572
7. Folstein M, Folsten S, McHugh P (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198. https://doi.org/10.1016/0022-0305(75)90088-8
8. Katz S, Down TD, Cash HR et al (1970) Progress in the development of the index of ADL. Gerontologist 10:20–30
9. WHO Coronavirus disease (2019) COVID-19 Situation Report – 43, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
10. Grasselli G, Pesenti A, Cecconi M (2020) Critical care utilization for the COVID-19 outbreak and forecast during an emergency response. JAMA 323:1545. https://doi.org/10.1001/jama.2020.4031
11. Coronavirus disease 2019 (COVID-19): situation report-57. Published March 17, 2020. https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/20200317-sitrep-57-covid-19.pdf?sfvrsn=a26922f2_2. Accessed March 18, 2020

12. Livingston E, Bucher K (2020) Coronavirus disease 2019 (COVID-19) in Italy. JAMA 323:1335. https://doi.org/10.1001/jama.2020.4344

13. Michaela A. C. Vollmer, Swapnil Mishra, H Juliette T Unwin (2020) Report 20: Using mobility to estimate the transmission intensity of COVID-19 in Italy: a subnational analysis with future scenarios. Imperial College COVID-19 Response Team May 2020

14. Signorelli C, Scognamiglio T, Odone A (2020) COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed 1:175–179. https://doi.org/10.23750/abm.v91i3-s.951

15. Norman DC (2016) Clinical features of infection in older adults. Clin Geriatr Med 32:433–441

16. Wester AL, Dunlop O, Melby KY et al (2013) Age-related differences in symptoms, diagnosis and prognosis of bacteremia. BMC Infect Dis 13:346. https://doi.org/10.1186/1471-2334-13-346

17. Metlay JP, Schulz R, Li Y et al (1997) Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 157:1453–1459. https://doi.org/10.1001/archinte.1997.0040340089009

18. Falsey AR, Baran A, Walsh EE (2015) Should clinical case definitions of influenza in hospitalized older adults include fever? Influenza Other Respir Viruses 9(Suppl 1):23–29

19. Wang L, He W, Yu X et al (2020) Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 80:639–645. https://doi.org/10.1016/j.jinf.2020.03.019

20. Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 180:934–943. https://doi.org/10.1001/jamainternmed.2020.0994

21. Inciardi RM, Adamo M, Lupi L et al (2020) Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J 41:1821–1829. https://doi.org/10.1093/eurheartj/ehaa310

22. Guan W, Ni Z, Hu Y (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032

23. Schiffirin EL, Fluck JM, Ito S et al (2020) Hypertension and COVID-19. Am J Hypertens 33:373–374. https://doi.org/10.1093/ajh/hpaaj057

24. Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21. https://doi.org/10.1016/s2213-2600(20)30116-8

25. Zhang P, Zhu L, Cai J et al (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126:1671–1681

26. Meng J, Xiao G, Zhang J et al (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9:757–760. https://doi.org/10.1080/22221751.2020.1746200

27. Italy: individuals aged 65 years and older vaccinated against flu 1990–2018 Published by Statista Research Department, Jan 14, 2020

28. Marano G, Pariani E, Luconi E et al (2020) Elderly people: propensity to be vaccinated for seasonal influenza in Italy. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2019.1706931

29. Li Q, Tang B, Bragazzi NL et al (2020) Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capability. Math Biosci 325:108378. https://doi.org/10.1016/j.mbs.2020.108378

30. Salem ML, El-Hennawy D (2020) The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19. Med Hypotheses 140:109752. https://doi.org/10.1016/j.mehy.2020.109752

31. Zeng Q, Langereis MA, van Vliet ALW et al (2008) Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci 105:9065–9069

32. Liotta G, Gilardi F, Scarcella P et al (2016) Trend and determinants of acute inpatient care for the elderly in Italy from 2001 to 2011. Annali di Igiene: Medicina Preventiva e di Comunità 28:319–327. https://doi.org/10.7416/ai.2016.2112

33. Czaja CA, Miller L, Alden N et al (2019) Age-related differences in hospitalization rates, clinical presentation, and outcomes among older adults hospitalized with influenza-U.S. influenza hospitalization surveillance network (FluSurv-NET). Open Forum Infect Dis 6:225. https://doi.org/10.1093/ofid/ofz225

34. Natale A, Ghio D, Tarchi D et al (2020) COVID-19 cases and case fatality rate by age. Knowledge for policy. https://ec.europa.eu/knowledge4policy/publication/covid-19-cases-case-fatality-rate-age_en. Accessed 11 May 2020

35. Bianchetti A, Rizzoni R, Guerini F et al (2020) Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging 15:1–3

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Salvatore Caratozzolo1 · Alberto Zucchelli2 · Marinella Turla3 · Maria Sofia Cotelli3 · Sara Fasceandini4 · Mara Zanni4 · Angelo Bianchetti5,14 · Matteo Peli P5,14 · Renzo Rizzoni6,14 · Stefano Boffelli6,14 · Melania Cappuccio7 · Federica Gottardi Psy7 · Chiara Vecchi Psy8 · Daniele Bellandi9 · Claudia Caminati9 · Simona Gentile10 · Elena Lucchi Psy10 · Ignaio Di Fazio11 · Marina Zanetti Psy11 · Giuliana Vezzadini12 · Chiara Forlani Psy12 · Maura Cosseddu Psy1 · Rosanna Turrone Psy1 · Silvia Pelizzari Psy1 · Andrea Scalvini1 · Marco Di Cesare1 · Marta Grigolo Psy7 · Lina Falanga6 · Nives Medici7 · Nives Palamini7 · Elisa Zanacchi Psy7 · Eleonora Grossi Psy10 · Giuseppe Bellelli13 · Alessandra Marenzoni2 · Marco Trabucchi14 · Alessandro Padovani1 · On behalf of COVIDEM Network

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
